Janux Therapeutics (NASDAQ:JANX) Posts Quarterly Earnings Results

Janux Therapeutics (NASDAQ:JANX - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13, Zacks reports. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

Janux Therapeutics Stock Performance

Shares of JANX traded down $1.06 during midday trading on Monday, hitting $31.83. The company had a trading volume of 866,965 shares, compared to its average volume of 1,021,134. Janux Therapeutics has a 1 year low of $31.36 and a 1 year high of $71.71. The firm has a market capitalization of $1.67 billion, a P/E ratio of -27.20 and a beta of 3.16. The company's 50-day simple moving average is $43.25 and its 200-day simple moving average is $47.86.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on JANX shares. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. BTIG Research upped their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Stifel Nicolaus lifted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. Finally, Wedbush reissued an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $88.00.

Remove Ads

Insider Buying and Selling

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm's stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the sale, the chief executive officer now directly owns 217,054 shares in the company, valued at $12,196,264.26. This trade represents a 10.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,668 shares of company stock worth $3,582,515. Company insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.